<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Alogliptin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06203</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (<span class="caps">DPP</span>-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (&gt;99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer.  <span class="caps">FDA</span> approved January 25, 2013.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06203/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06203/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06203.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06203.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06203.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06203.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06203.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06203">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>SYR-322</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Alogliptin Benzoate </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000007/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000007/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: KEJICOXJTRHYAK-XFULWGLBSA-N</li>
              <li>Monoisotopic Mass: 461.206304377</li>
              <li>Average Mass: 461.513</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000007">DBSALT000007</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Nesina </td><td>Takeda Pharms USA</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Kazano </td><td>Alogliptin and Metformin hydrochloride</td></tr><tr><td>Oseni </td><td>Alogliptin and Pioglitazone hydrochloride</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/dipeptidyl-peptidase-iv-inhibitors">Dipeptidyl-Peptidase IV Inhibitors</a></li>
<li><a href="/mesh/antidiabetic-agents">Antidiabetic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>850649-61-5</td></tr><tr><th>Weight</th><td>Average: 339.3916<br>Monoisotopic: 339.169524941</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>ZSBOMTDTBDDKMP-OAHLLOKOSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzonitriles</td></tr><tr><th>Direct parent</th><td>Benzonitriles</td></tr><tr><th>Alternative parents</th><td>Aminopiperidines; Aminopyrimidines and Derivatives; Pyrimidones; Hydropyrimidines; Tertiary Amines; Nitriles; Polyamines; Monoalkylamines</td></tr><tr><th>Substituents</th><td>aminopyrimidine; pyrimidone; 3-aminopiperidine; hydropyrimidine; pyrimidine; piperidine; tertiary amine; nitrile; carbonitrile; polyamine; amine; primary aliphatic amine; primary amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzonitriles. These are organic compounds containing a benzene bearing a nitrile substituent.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. </td></tr><tr><th>Pharmacodynamics</th><td>Peak inhibition of DPP-4 occurs within 2-3 hours after a single-dose administration to healthy subjects. The peak inhibition of DPP-4 exceeded 93% across doses of 12.5 mg to 800 mg. Inhibition of DPP-4 remained above 80% at 24 hours for doses greater than or equal to 25 mg.  Alogliptin also demonstrated decreases in postprandial glucagon while increasing postprandial active GLP-1 levels compared to placebo over an 8-hour period following a standardized meal. Alogliptin does not affect the QTc interval. </td></tr><tr><th>Mechanism of action</th><td>Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.</td></tr><tr><th>Absorption</th><td>The pharmacokinetics of NESINA was also shown to be similar in healthy subjects and in patients with type 2 diabetes. When single, oral doses up to 800 mg in healthy subjects and type 2 diabetes patients are given, the peak plasma alogliptin concentration (median Tmax) occurred 1 to 2 hours after dosing. Accumulation of aloglipin is minimal. The absolute bioavailability of NESINA is approximately 100%. Food does not affect the absorption of alogliptin. 
</td></tr><tr><th>Volume of distribution</th><td><p>Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.</p></td></tr><tr><th>Protein binding</th><td>Alogliptin is 20% bound to plasma proteins.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Alogliptin does not undergo extensive metabolism. Two minor metabolites that were detected are N-demethylated alogliptin (</p></td></tr><tr><th>Route of elimination</th><td>Renal excretion (76%) and feces (13%).  60% to 71% of the dose is excreted as unchanged drug in the urine.</td></tr><tr><th>Half life</th><td>Terminal half-life = 21 hours </td></tr><tr><th>Clearance</th><td><p>Renal clearance = 9.6 L/h (this value indicates some active renal tubular secretion);<br>
Systemic clearance = 14.0 L/h.</p></td></tr><tr><th>Toxicity</th><td>Common adverse reactions (reported in &#8805;4% of patients treated with alogliptin 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache, and upper respiratory tract infection. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9942</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9738</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5492</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6453</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6811</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9238</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.591</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8003</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7259</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5528</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9169</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8475</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9038</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8527</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7608</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9363</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5595
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8887
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9931
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5603 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.5507
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8389
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>6.25 mg, 12.5 mg, 25 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>